The group is currently focusing on putting into practice ALK translocation, studying how effective PI3K/mTOR inhibitors are in patients with EGFR-TKI-resistant lung cancer, and studying how effective PARP inhibitors are in lung cancer.

They are analysing the epidemiological and clinical characteristics of women diagnosed with lung cancer. They are committed to reinforcing a multidisciplinary approach to provide the best care for patients, and are proactive in the fight against smoking.

Visit the research group’s page


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.